

**Table 1.** Characteristics of the subjects before and after evolocumab treatment. Data are indicated as mean  $\pm$  SD. Mean absolute changes from baseline to week 12 are shown with  $\pm$  SD and mean percentage changes are indicated in parenthesis. P-values were calculated using a paired difference

	Before	After	Change	P-value
Weight (kg)	82.7 $\pm$ 16	82.8 $\pm$ 15	0.1 $\pm$ 1.3 (0.15%)	0.74
BMI (kg/m <sup>2</sup> )	29.4 $\pm$ 4	29.4 $\pm$ 3.7	0.1 $\pm$ 0.4 (0.18%)	0.68
Waist (cm)	104 $\pm$ 9.9	104 $\pm$ 9.6	-0.04 $\pm$ 2.6 (-0.037%)	0.96
Systolic BP (mmHg)	138 $\pm$ 16	135 $\pm$ 16	-3.7 $\pm$ 13 (-2.7%)	0.31
Diastolic BP (mmHg)	83.8 $\pm$ 6.8	79.7 $\pm$ 6.6	-4.2 $\pm$ 7.4 (-5%)	0.064
Heart rate (bpm)	66.5 $\pm$ 10	69.4 $\pm$ 10	2.8 $\pm$ 8.3 (4.3%)	0.24
VAT (cm <sup>3</sup> )	2420 $\pm$ 960	2450 $\pm$ 1100	-13.3 $\pm$ 230 (-0.55%)	0.84
SAT (cm <sup>3</sup> )	3900 $\pm$ 1700	4110 $\pm$ 1600	8.5 $\pm$ 120 (0.22%)	0.81
<b>Glucose homeostasis</b>				
P-Glucose (mmol/l)	6.3 $\pm$ 0.4	6.4 $\pm$ 0.8	0.1 $\pm$ 0.5 (1.8%)	0.39
HbA1c (%)	5.9 $\pm$ 0.4	6.1 $\pm$ 0.5	0.2 $\pm$ 0.3 (3.3%)	0.061
Insulin ( $\mu$ U/ml)	8.9 $\pm$ 3.6	10.3 $\pm$ 7	1.4 $\pm$ 4.9 (16%)	0.31
HOMA2-%B	66.9 $\pm$ 18	65.4 $\pm$ 17	-1.5 $\pm$ 17 (-2.2%)	0.75
HOMA2-%S	98.8 $\pm$ 56	99.6 $\pm$ 53	0.8 $\pm$ 41 (0.83%)	0.94
HOMA2-IR	1.4 $\pm$ 0.98	1.2 $\pm$ 0.5	-0.2 $\pm$ 0.7 (-14%)	0.30
<b>Lipids and lipoproteins</b>				
Cholesterol (mmol/l)	3.9 $\pm$ 0.5	2.2 $\pm$ 0.6	-1.7 $\pm$ 0.4 (-42%)	<b>&lt;0.001</b>
HDL-C (mmol/l)	1.4 $\pm$ 0.4	1.6 $\pm$ 0.4	0.2 $\pm$ 0.2 (16%)	<b>&lt;0.001</b>
Triglycerides (mmol/l)	1.6 $\pm$ 0.5	1.3 $\pm$ 0.5	-0.2 $\pm$ 0.6 (-14%)	0.18
LDL-C (mmol/l)	1.7 $\pm$ 0.4	0.4 $\pm$ 0.2	-1.4 $\pm$ 0.4 (-78%)	<b>&lt;0.001</b>
ApoC-III (mg/dl)	12.2 $\pm$ 4.3	10.4 $\pm$ 5.2	-1.9 $\pm$ 3.7 (-15%)	0.093
ApoB (mg/dl)	75.9 $\pm$ 15	35.3 $\pm$ 11	-40.5 $\pm$ 8.8 (-53%)	<b>&lt;0.001</b>
ApoB48 (mg/l)	6.1 $\pm$ 3.8	5.3 $\pm$ 3.3	-0.8 $\pm$ 2.5 (-13%)	0.27
ApoA-I (mg/dl)	142 $\pm$ 25	151 $\pm$ 26	9.5 $\pm$ 11 (6.7%)	<b>0.011</b>
TRL-C (mg/dl)	33.4 $\pm$ 11	17.8 $\pm$ 6.5	-15.6 $\pm$ 7.8 (-47%)	<b>&lt;0.001</b>
RLP-C (mg/dl)	8.5 $\pm$ 4.3	7.0 $\pm$ 4.7	-1.4 $\pm$ 4.4 (-17%)	0.27
<b>Hepatic lipid metabolism</b>				
DNL ( $\mu$ mol/l)	17.6 $\pm$ 13	17.1 $\pm$ 12	-0.48 $\pm$ 13 (-2.7%)	0.90
NEFA ( $\mu$ mol/l)	615 $\pm$ 210	608 $\pm$ 180	-7.2 $\pm$ 190 (-1.2%)	0.89
$\beta$ -OHB (mg/dl)	0.67 $\pm$ 0.24	0.73 $\pm$ 0.32	0.05 $\pm$ 0.34 (7.9%)	0.59
Liver fat (%)	6.6 $\pm$ 6.6	6.3 $\pm$ 7.2	-0.2 $\pm$ 1 (-2.5%)	0.59
LPL activity (mU/ml)	134 $\pm$ 52	122 $\pm$ 44	-12 $\pm$ 53 (-1.9%)	0.44
HL activity (mU/ml)	227 $\pm$ 110	220 $\pm$ 89	-9 $\pm$ 65 (4.5%)	0.64

t-test and p-values <0.05 are indicated in bold.